{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:15:23Z","timestamp":1792095323736,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002922"],"award-info":[{"award-number":["ZIAMH002922"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA DC000064"],"award-info":[{"award-number":["ZIA DC000064"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.prro.2025.12.015","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:10:23Z","timestamp":1770192623000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-120X","authenticated-orcid":false,"given":"Peter","family":"Mathen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra V.","family":"Krauze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Cooley-Zgela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Shankavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DeeDee","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Camphausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.12.015_bib0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0002","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0003","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0004","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","article-title":"Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status","volume":"27","author":"Brandes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11060-010-0251-4","article-title":"Radiographic patterns of relapse in glioblastoma","volume":"101","author":"Chamberlain","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0006","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.755","article-title":"Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme","volume":"18","author":"Easaw","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0007","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.755430","article-title":"Complete and incomplete resection for progressive glioblastoma prolongs post-progression survival","volume":"12","author":"Behling","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0009","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10143-020-01331-1","article-title":"Assessing the efficacy of repeat resections in recurrent glioblastoma: A systematic review","volume":"44","author":"Botros","year":"2021","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.prro.2025.12.015_bib0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/02688690802182256","article-title":"Recurrent' glioblastoma multiforme, when should we reoperate?","volume":"22","author":"Barbagallo","year":"2008","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.prro.2025.12.015_bib0011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fneur.2019.00286","article-title":"A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: Time to consider the timing of reoperation","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.prro.2025.12.015_bib0012","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0013","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.4103\/2152-7806.151331","article-title":"The future of high-grade glioma: Where we are and where are we going","volume":"6","author":"Le Rhun","year":"2015","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.prro.2025.12.015_bib0014","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0015","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.12.015_bib0016","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/now035","article-title":"AVAREG: A phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0017","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.21873\/anticanres.12954","article-title":"Technical advances in radiation therapy for brain tumors","volume":"38","author":"Scaringi","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prro.2025.12.015_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0019","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2007.08.015","article-title":"Reirradiation tolerance of the human brain","volume":"70","author":"Mayer","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.015_bib0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-018-03059-x","article-title":"Re-irradiation for recurrent glioma: Outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)","volume":"142","author":"Navarria","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0021","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13014-017-0930-9","article-title":"Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system","volume":"12","author":"Krauze","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-023-04340-4","article-title":"Re-irradiation for recurrent high-grade glioma: An analysis of prognostic factors for survival and predictors of radiation necrosis","volume":"163","author":"Moore-Palhares","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13014-017-0928-3","article-title":"Expert consensus on re-irradiation for recurrent glioma","volume":"12","author":"Krauze","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0024","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1200\/JCO.22.01785","article-title":"Reirradiation for recurrent glioblastoma: What we know and what we do not","volume":"41","author":"Knisely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0025","series-title":"Cavenee WK. World Health Organization Histological Classification of Tumours of the Central Nervous System","author":"Louis","year":"2016"},{"key":"10.1016\/j.prro.2025.12.015_bib0026","article-title":"Protocol: Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology\/RTOG 1205","volume":"105","author":"Tsien","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \"target delineation of glioblastomas\"","volume":"118","author":"Niyazi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0028","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0029","series-title":"R: A Language and Environment for Statistical Computing","year":"2025"},{"key":"10.1016\/j.prro.2025.12.015_bib0030","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.prro.2025.12.015_bib0031","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0360-3016(98)00416-7","article-title":"A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma","volume":"43","author":"Hudes","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.015_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2017.09.039","article-title":"Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial","volume":"125","author":"M\u00f8ller","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2017.06.2466","article-title":"Multicenter, phase 1, dose escalation study of hypofractionated stereotactic radiation therapy with bevacizumab for recurrent glioblastoma and anaplastic astrocytoma","volume":"99","author":"Clarke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.015_bib0034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): A systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1200\/JCO.2000.18.3.646","article-title":"Cognitive function as a predictor of survival in patients with recurrent malignant glioma","volume":"18","author":"Meyers","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0036","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0360-3016(89)90518-X","article-title":"Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas","volume":"17","author":"Leibel","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.015_bib0037","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jnnp.2004.036186","article-title":"Facets and determinants of quality of life in patients with recurrent high grade glioma","volume":"76","author":"Giovagnoli","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.prro.2025.12.015_bib0038","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-014-1574-3","article-title":"Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients","volume":"120","author":"Peters","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0039","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2010-0105","article-title":"Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study","volume":"15","author":"Vredenburgh","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.prro.2025.12.015_bib0040","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0360-3016(99)00336-3","article-title":"Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas","volume":"45","author":"Cho","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.015_bib0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11060-006-9231-0","article-title":"Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma","volume":"81","author":"Ernst-Stecken","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0042","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-019-03320-x","article-title":"Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients","volume":"145","author":"Wick","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2025.12.015_bib0043","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COC.0b013e31815e3fdc","article-title":"Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma","volume":"31","author":"Nieder","year":"2008","journal-title":"Am J Clin Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:35:10Z","timestamp":1778063710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1879850026000147"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.12.015","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}